Raúl Mondesí Suspended 50 Games For PEDs
Photo via Morry Gash/ [object Object] Top Kansas City Royals prospect Raúl Mondesí was suspended for 50 games Thursday, after testing positive for the performance enhancing drug clenbuterol. According to Mondesí, an over-the-counter flu medication he ingested in the Dominican Republic caused the positive:
I took an over-the-counter medication [Subrox-C], which I bought in the Dominican Republic to treat cold and flu symptoms. I failed to read the labeling on the medication or consult with my trainer or team about taking it and did not know it contained a banned substance. I tested positive for that banned substance, with a minuscule amount of Clenbuterol in my system, which could not have possibly enhanced my performance on the field, and now must face the consequences of that mistake.
According to the New York Post’s Joel Sherman, the original suspension was for 80 games, but MLB and the MLBPA agreed to a reduction after Mondesí. showed evidence of the banned substance in the medication he says he took:
Correction: This post originally stated that Raúl Mondesí Jr. tested positive for PEDs. It was actually Raúl A. Mondesí that tested positive; Raúl Mondesí Jr. is his brother, who was formerly in the Milwaukee Brewers system. Both are sons of former major leaguer Raúl Mondesí.
Why Mark DeRosa Should Never Work in Baseball Again
What Is the College Basketball Crown and Why It’s Struggling
Miami (OH) vs SMU Prediction: Best Bet for NCAA Play-In Game
MLB Home Run Leader Future Picks: Best Bets for 2026 Season
Early NFL Free Agency Winners and Moves That Stand Out
- Top NBA Picks for Today: Thunder vs Magic, Cavs vs Bucks, Nuggets vs 76ers
- Best Future Bets for MLB Strikeout Leader: Crochet, Gilbert, and Cease
- Top NBA Picks Today: Betting Predictions for Monday’s NBA Slate
- Best NCAA Tournament Championship Future Betting Picks Before Selection Sunday
- Sunday NBA Odds and Betting Picks for March 15th
- UFC Vegas 114 Betting Preview: Three Best Bets for Fight Night
- Free NBA Picks for March 14: Three Bets to Target

